1. Public page

Public page

Lutathera® (lutetium [177Lu] oxodotreotide)

Where can I get more information about Lutathera®?

Great Britain summary of product characteristics (SmPC)

Great Britain patient information leaflet (PIL)

Northern Ireland summary of product characteristics (SmPC)

Northern Ireland patient information leaflet (PIL)

These links will take you to the electronic medicines compendium (emc) websites, which are not Novartis websites.

 

NCUK patient support leaflet

 

Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan)

Where can I get more information about Pluvicto®?

Great Britain summary of product characteristics (SmPC)

Great Britain patient information leaflet (PIL)

These links will take you to the electronic medicines compendium (emc) websites, which are not Novartis websites.

 

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See yellowcard.mhra.gov.uk for how to report side effects.

FA-11233539 | UK | August 2024
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You should also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.